Cervical Cancer

Cervical Cancer: treatments, trials & survival

Cervical cancer is largely preventable through HPV vaccination and screening. Learn about treatment options, immunotherapy advances, and clinical trials.

New Cases (2024)
13,820
5-Yr Survival
67.2%
Annual Deaths
4,360
Trend
Decreasing
See active trials

About Cervical Cancer

Cervical cancer is largely preventable through HPV vaccination and screening. Learn about treatment options, immunotherapy advances, and clinical trials.

According to the National Cancer Institute’s SEER database, an estimated 13,820 new cases of cervical cancer will be diagnosed in the United States in 2024, with approximately 4,360 deaths. The overall 5-year relative survival rate is 67.2%.

Source: NCI SEER Data: 1975–2022

Treatment options

Current treatment approaches for cervical cancer depend on the stage at diagnosis, tumor characteristics, and the patient’s overall health. The most common options include:

1
Surgery (Hysterectomy, Trachelectomy)
2
Radiation Therapy
3
Chemotherapy (Cisplatin)
4
Immunotherapy (Pembrolizumab)
5
Targeted Therapy (Bevacizumab)
6
Chemoradiation

Treatment recommendations should always be discussed with a qualified oncologist. The options listed above are based on current clinical guidelines and may vary case by case.

Stages

Staging describes the extent of cancer in the body and is crucial for planning the most appropriate treatment:

Stage I Stage II Stage III Stage IV

Known risk factors

Understanding risk factors can support prevention and early detection. Known risk factors for this cancer include:

HPV infection
Smoking
Weakened immune system
Multiple sexual partners
Long-term oral contraceptive use
Multiple pregnancies

Not sure where to start?

A patient navigator familiar with cervical cancer can help you understand your options and connect you with top US hospitals. Free & confidential.

Active clinical trials

Clinical trials offer access to cutting-edge treatments not yet widely available. The trials below are sourced in real time from ClinicalTrials.gov:

Frequently asked questions

The 5-year relative survival rate for cervical cancer is 67.2%. When caught at the localized stage, survival is 92%.
Yes, HPV vaccination prevents most cervical cancers. Regular Pap tests and HPV testing allow early detection of precancerous changes. The HPV vaccine is recommended for ages 9-26.
Pembrolizumab is FDA-approved for recurrent/metastatic cervical cancer with PD-L1 expression. It is used in combination with chemotherapy and bevacizumab as first-line treatment for advanced disease.
A radical trachelectomy removes the cervix while preserving the uterus, allowing future pregnancies. It is an option for early-stage cervical cancer in women who wish to maintain fertility.
You’re not alone

Looking for cervical cancer treatment options?

A patient navigator can help you explore treatment pathways, find clinical trials near you, and connect with specialists who see cervical cancer every day. Free, confidential consultation.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.